Physician profile
Scott Berger
NPI 1093343246
$4,137.34
in general payments reported to CMS, 2019-2025
19 companies · $1,924 in 2025
The $1,924 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $215 · 2023: $232 · 2024: $1,767 · 2025: $1,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,791 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,790.68 |
| Education | $131.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $710.79 | 2023-2025 | Skyrizi |
| Genzyme Corporation | $709.73 | 2023-2025 | |
| Janssen Biotech, INC. | $552.27 | 2024-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $297.13 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $281.29 | 2023-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $241.33 | 2024-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $214.51 | 2024-2025 | Gattex, Entyvio, Eohilia |
| Intercept Pharmaceuticals, INC. | $211.40 | 2022-2024 | |
| Ardelyx, INC. | $194.47 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $156.85 | 2024-2025 | Rezdiffra |
| Gilead Sciences, INC. | $124.40 | 2022 | |
| Boston Scientific Corporation | $115.68 | 2024 | Apollo Esg Nxt System |
| Celltrion USA INC. | $90.11 | 2023-2025 | Vegzelma, Yuflyma |
| Aimmune Therapeutics, INC. | $90.06 | 2025 | Zenpep |
| Pfizer INC. | $39.25 | 2023-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.73 | 2024 | Xifaxan |
| Lilly USA, LLC | $30.01 | 2025 | Omvoh |
| Dynavax Technologies Corporation | $26.03 | 2025 | Heplisav-B |
| Braintree Laboratories, INC. | $16.30 | 2024 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.